and technological innovation. In undertaking these duties, the Commission seeks to identify and examine specific bioethical, legal, and social issues related to potential scientific and technological advances; examine diverse perspectives and possibilities for international collaboration on these issues; and recommend legal, regulatory, or policy actions as appropriate.

The Commission has begun a review of the current rules and standards for protecting human subjects in scientific studies supported by the Federal Government. The President requested this study on November 24, 2010, following revelations that the U.S. Public Health Service supported research on sexually transmitted diseases in Guatemala from 1946 to 1948 involving the intentional infection of vulnerable populations. President Obama asked the Commission Chair “to convene a panel to conduct * * * a thorough review of human subjects protection to determine if Federal regulations and international standards adequately guard the health and well-being of participants in scientific studies supported by the Federal Government.”

The President charged the Commission to seek the insights and perspective of international experts and consult with counterparts in the global community. The Commission will provide the President with a report of its findings and recommendations later this year.

To implement this mission, the Commission wishes to develop a thorough understanding of the current U.S. and international standards for protecting the health and well-being of participants in scientific studies supported by the Federal Government. To this end, the Commission is inviting interested parties to provide input and advice through written comments. Among other issues, the Commission is interested in receiving comments on the existing standards for protecting human subjects, both domestically and internationally; how the current system of global research works in practice; and the ethical and social justice issues that emerge from the current research system. Comments concerning the benefits of medical research; differences across global norms and standards; standards for ancillary care and post-trial access to treatment; trial design; duties to participants; challenges, if any, faced by U.S.-funded researchers working internationally, or international researchers working on U.S.-funded research; and other specific information are all especially welcome.

The Commission is under a very tight deadline and would appreciate comments within 60 days.

Please address comments by e-mail to info@bioethics.gov, or by mail to the following address: Public Commentary, The Presidential Commission for the Study of Bioethical Issues, 1425 New York Ave. NW., Suite C–100, Washington, DC 20005. Comments will be publicly available, including any personally identifiable or confidential business information that they contain. Trade secrets should not be submitted.

Dated: February 17, 2011.

Valerie H. Bonham,
Executive Director, The Presidential Commission for the Study of Bioethical Issues.

[FR Doc. 2011–4658 Filed 3–1–11; 8:45 am] BILLING CODE 4154–06–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Subcommittee on Procedures Review, Advisory Board on Radiation and Worker Health (ABRW, National Institute for Occupational Safety and Health (NIOSH))

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following meeting for the aforementioned subgroup:

Time and Date: 9 a.m.–5 p.m., March 22, 2011.

Place: Cincinnati Airport Marriott, 2395 Progress Drive, Hebron, KY 41018. Telephone (859) 334–4611, Fax (859) 334–4619.

Status: Open to the public, but without a public comment period. To access by conference call dial the following information: (866) 659–0537, Participant Pass Code 9933701.

Background: The ABRWH was established under the Energy Employees Occupational Illness Compensation Program Act of 2000 to advise the President on a variety of policy and technical functions required to implement and effectively manage the dose reconstruction process by the Department of Energy. The ABRWH includes providing advice to the Secretary, HHS, on the scientific validity and quality of dose reconstruction efforts performed for this program; and (c) upon request by the Secretary, HHS, advising the Secretary on whether there is a class of federal employees at any Department of Energy facility who were exposed to radiation but for whom it is not feasible to estimate their radiation dose, and on whether there is a reasonable likelihood that such radiation doses may have endangered the health of members of this class. The Subcommittee on Procedures Review was established to aid the ABRWH in carrying out its duty to advise the Secretary, HHS, on dose reconstructions. The Subcommittee on Procedures Review is responsible for overseeing, tracking, and participating in the reviews of all procedures used in the dose reconstruction process by the NIOSH Division of Compensation Analysis and Support (DCAS) and its dose reconstruction contractor.

shall advise the Secretary and the Congress concerning the award of grants and loans related to Section 1322 of the Affordable Care Act, which provides for a Federal program to assist establishment and operation of nonprofit, member-run health insurance issuers. In these matters, the Committee shall consult with all components of the Department, other federal entities, and non-Federal organizations, as appropriate; and examine relevant data sources to assess the grant and loan award strategy to provide recommendations to CCIIO.

**DATES:** Meeting Date: March 14, 2011 from 8:30 a.m. to 5 p.m., Eastern Standard Time (EST) Deadline for Meeting Registration, Presentations and Comments: March 10, 2011, 5 p.m. EST. Deadline for Requesting Special Accommodations: March 10, 2011, 5 p.m., EST.

**ADDRESSES:** Meeting Location: Madison Hotel, 1177 15th Street, NW., Washington, DC 20005.

**Meeting Online Access:** To participate in this meeting via the Internet, go to [http://www.readyshow.com/](http://www.readyshow.com/) and enter participant code 49888151. Note that audio of the meeting will only be broadcast through the conference phone line.

**Meeting Phone Access:** To participate in this meeting via phone, please dial into the toll free phone number 1–888–299–4099, and provide the following code to the operator: VW38426.

**Meeting Registration, Presentations, and Written Comments:** Anne Bollinger, Center for Consumer Information and Insurance Oversight, CMS, 200 Independence Avenue, SW., Washington, DC 20201, 301–492–395, Fax: 301–492–4462, or contact by e-mail at anne.bollinger@hhs.gov. Written comments must be submitted in Word format.

**Registration:** The meeting is open to the public, but attendance is limited to the space available. Persons wishing to attend this meeting must register by contacting the designated Federal official at the address listed in the ADDRESSES section of this notice by telephone at the number listed in the FOR FURTHER INFORMATION CONTACT section of this notice, by the date listed in the DATES section of this notice.

**FOR FURTHER INFORMATION CONTACT:** Anne Bollinger, 301–492–4395. Press inquiries are handled through CCIIO’s Press Office at (202) 690–6343.

**SUPPLEMENTARY INFORMATION:**

### I. Background

The purpose of the meeting is to assist and advise the Secretary and the Congress on the Department’s strategy to foster the creation of qualified nonprofit health insurance issuers. Specifically, the Committee

The Committee shall advise the Secretary and the Congress concerning the award of grants and loans related to Section 1322 of the Affordable Care Act, which provides for a Federal program to assist establishment and operation of nonprofit, member-run health insurance issuers. In these matters, the Committee shall consult with all components of the Department, other federal entities, and non-Federal organizations, as appropriate; and examine relevant data sources to assess the grant and loan award strategy to provide recommendations to CCIIO.

**II. Meeting Agenda**

The Committee will hear comments from the public and then begin deliberations on proposed recommendations presented by the work groups from the Committee. CCIIO intends to make background material available to the public no later than two (2) business days prior to the meeting. If CCIIO is unable to post the background material on its Web site prior to the meeting, it will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on CCIIO’s Web site after the meeting, at [http://hhs.gov/CCIIO](http://hhs.gov/CCIIO).

Oral comments from the public will be scheduled between approximately 8:30 a.m.–9:30 a.m. Individuals or organizations that wish to make a 3-minute oral presentation on an agenda topic should submit a written copy in Word format of the oral presentation to the designated federal official (DFO) at the address listed in the ADDRESSES section of this notice by the date listed in the DATES section of this notice. The number of oral presentations may be limited by the time available. Persons attending CCIIO’s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. If the number of speakers requesting to comment is greater than can be reasonably accommodated during the scheduled open public comment session, CCIIO will take written comments after the meeting until close of business. Individuals not wishing to make a presentation may submit written comments in Word format to the DFO at the address listed in the ADDRESSES section of this notice by the date listed in the DATES section of this notice.

Individuals requiring sign language interpretation or other special accommodations must contact the DFO via the contact information specified in